DCM
KURA icon

DAFNA Capital Management’s Kura Oncology KURA Stock Holding History

DAFNA Capital Management’s Portfolio KURA Stock Details KURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.32M Sell
120,568
-115,300
-49% -$1.09M 0.25% 59
2026
Q1 		$1.92M Hold
235,868
– – 0.44% 48
2025
Q4 		$2.45M Sell
235,868
-227,500
-49% -$2.39M 0.57% 43
2025
Q3 		$4.1M Hold
463,368
– – 1.01% 24
2025
Q2 		$2.67M Hold
463,368
– – 0.74% 34
2025
Q1 		$3.06M Buy
463,368
+15,000
+3% +$117K 0.87% 30
2024
Q4 		$3.91M Buy
448,368
+40,000
+10% +$576K 0.99% 26
2024
Q3 		$7.98M Sell
408,368
-15,132
-4% -$307K 1.89% 19
2024
Q2 		$8.72M Buy
423,500
+10,837
+3% +$223K 2.08% 17
2024
Q1 		$8.8M Sell
412,663
-80,021
-16% -$1.56M 2% 18
2023
Q4 		$7.08M Sell
492,684
-58,100
-11% -$571K 1.7% 18
2023
Q3 		$5.02M Buy
550,784
+193,000
+54% +$1.96M 1.56% 20
2023
Q2 		$3.79M Buy
357,784
+248,000
+226% +$2.93M 1.04% 31
2023
Q1 		$1.34M Sell
109,784
-35,000
-24% -$437K 0.4% 42
2022
Q4 		$1.8M Sell
144,784
-61,545
-30% -$895K 0.51% 48
2022
Q3 		$2.82M Buy
206,329
+88,500
+75% +$1.37M 0.76% 36
2022
Q2 		$2.16M Buy
117,829
+4,500
+4% +$64.7K 0.59% 45
2022
Q1 		$1.82M Buy
113,329
+2,500
+2% +$36.1K 0.47% 49
2021
Q4 		$1.55M Buy
110,829
+10,000
+10% +$162K 0.39% 51
2021
Q3 		$1.89M Buy
100,829
+17,300
+21% +$326K 0.5% 49
2021
Q2 		$1.74M Buy
83,529
+31,729
+61% +$788K 0.36% 54
2021
Q1 		$1.46M Buy
51,800
+42,800
+476% +$1.35M 0.35% 66
2020
Q4 		$294K Sell
9,000
-30,019
-77% -$1.05M 0.09% 71
2020
Q3 		$1.2M Sell
39,019
-255,241
-87% -$5.64M 0.39% 52
2020
Q2 		$4.8M Sell
294,260
-13,281
-4% -$192K 1.38% 24
2020
Q1 		$3.06M Buy
307,541
+134,066
+77% +$1.53M 1.28% 25
2019
Q4 		$2.38M Buy
173,475
+69,817
+67% +$1.03M 0.82% 29
2019
Q3 		$1.57M Buy
103,658
+56,416
+119% +$1M 0.59% 44
2019
Q2 		$930K Buy
47,242
+10,684
+29% +$177K 0.35% 60
2019
Q1 		$606K Sell
36,558
-112,059
-75% -$1.73M 0.26% 62
2018
Q4 		$2.09M Sell
148,617
-91,883
-38% -$1.22M 1.04% 29
2018
Q3 		$4.21M Buy
240,500
+1,000
+0.4% +$19.2K 1.73% 20
2018
Q2 		$4.36M Buy
239,500
+112,500
+89% +$1.91M 2.04% 14
2018
Q1 		$2.38M Buy
127,000
+9,719
+8% +$189K 1.16% 27
2017
Q4 		$1.79M Buy
117,281
+11,422
+11% +$168K 0.97% 34
2017
Q3 		$1.58M Buy
+105,859
New +$994K 0.98% 35

Other funds holding KURA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

DAFNA Capital Management's KURA Position: Q2 2026 in Review

DAFNA Capital Management reduced its Kura Oncology (KURA) stake by 49% in Q2 2026, selling an estimated $1.09M and leaving 120,568 shares worth $1.32M. The position accounts for 0.25% of the portfolio, ranked #59.

DAFNA Capital Management first reported a position in KURA in Q3 2017 and has held it in 36 quarters since. The position peaked at $8.8M in Q1 2024. 220 funds tracked by Wall St. Rank hold KURA as of Q2 2026.

  • DAFNA Capital Management held 120,568 shares of Kura Oncology worth $1.32M as of Q2 2026.
  • DAFNA Capital Management sold 115,300 Kura Oncology shares in Q2 2026, an estimated $1.09M.
  • Kura Oncology made up 0.25% of DAFNA Capital Management's portfolio in Q2 2026, its #59 holding.
  • DAFNA Capital Management first reported a position in Kura Oncology in Q3 2017 and has held it in 36 quarters since.
  • DAFNA Capital Management's Kura Oncology position peaked at $8.8M in Q1 2024.
  • 220 funds tracked by Wall St. Rank held Kura Oncology as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.